Attached files
| file | filename |
|---|---|
| EX-23.1 - EXHIBIT 23.1 - Brooklyn ImmunoTherapeutics, Inc. | nt10023650x1_ex23-1.htm |
| EX-21.1 - EXHIBIT 21.1 - Brooklyn ImmunoTherapeutics, Inc. | nt10023650x1_ex21-1.htm |
| EX-10.9(A) - EXHIBIT 10.9(A) - Brooklyn ImmunoTherapeutics, Inc. | nt10023650x1_ex10-9a.htm |
| EX-5.1 - EXHIBIT 5.1 - Brooklyn ImmunoTherapeutics, Inc. | nt10023650x1_ex5-1.htm |
| EX-4.2 - EXHIBIT 4.2 - Brooklyn ImmunoTherapeutics, Inc. | nt10023650x1_ex4-2.htm |
| EX-4.1 - EXHIBIT 4.1 - Brooklyn ImmunoTherapeutics, Inc. | nt10023650x1_ex4-1.htm |
| S-1 - S-1 - Brooklyn ImmunoTherapeutics, Inc. | nt10023650x1_s1.htm |
Exhibit 23.2
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
We consent to the incorporation by reference in this Registration Statement of Brooklyn ImmunoTherapeutics, Inc. on Form S-1 of our report dated April 28, 2021, with
respect to our audits of the financial statements of Brooklyn ImmunoTherapeutics, LLC as of December 31, 2020 and 2019 and for each of the two years in the period ended December 31, 2020 appearing in Form 8-K/A of Brooklyn ImmunoTherapeutics, Inc.
dated April 30, 2021. We also consent to the reference to our firm under the heading “Experts” in the Prospectus, which is part of this Registration Statement.
Our report on the financial statements refers to a change in the method of accounting for leases in 2020 due to the adoption of the guidance in ASC Topic 842, Leases
(“Topic 842”).
/s/ Marcum llp
Marcum llp
New York, NY
April 30, 2021